{"filings":[{"id":470801,"accession_number":"0001651308-26-000012","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2026-05-15T20:08:07+00:00","items":["8.01","9.01"],"status":"ready","headline":"BeOne Medicines gets FDA accelerated approval for BEQALZI (sonrotoclax) in R/R MCL","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved BEQALZI for R/R mantle cell lymphoma after ≥2 prior therapies including a BTK inhibitor.","Phase 1/2 trial showed ORR 52%, CR 16%, median DOR 15.8 months; safety generally well tolerated.","Continued approval contingent on confirmatory CELESTIAL-RRMCL trial (NCT06742996) now underway.","BEQALZI is the first new BCL2 inhibitor approved in the U.S. in a decade and the only one for MCL.","Also approved in China for R/R MCL and CLL/SLL; EMA review ongoing; Fast Track for Waldenström."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94413,"accession_number":"0001628280-26-030866","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BeOne Q1 2026: revenue $1.5B (+35%), BRUKINSA $1.1B (+38%), diluted EPS $1.96/$3.24","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total global revenue $1.5B for Q1 2026, up 35% from prior year.","BRUKINSA global revenue $1.1B, up 38% YoY, maintains BTKi leadership.","GAAP diluted EPS $1.96 (vs $0.01); non-GAAP diluted EPS $3.24 (vs $1.22).","GAAP net income $227M (vs $1.3M); adjusted net income $375M (vs $136M).","Free cash flow $161M, turnaround from negative $12M in prior year."],"consensus_eps_estimate":null,"consensus_eps_actual":0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":1513438000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94412,"accession_number":"0001651308-26-000008","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2026-04-14T23:59:59+00:00","items":["2.02"],"status":"ready","headline":"BeOne Medicines reports FY2025 revenue $5.34B, R&D spend $2.15B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $5.34B, up 40% YoY; gross margin 87.5% (China 66.6%, ex-China 97.0%)","R&D total $2.15B, up 10% YoY; largest pipeline: sonrotoclax $176.7M, BRUKINSA $97.6M","Key product production 6.27M vials, sales 5.99M vials; inventory 2.91M vials at Dec 31, 2025","U.S. GAAP vs PRC GAAP differences: stock compensation and lease accounting treatments vary"],"consensus_eps_estimate":null,"consensus_eps_actual":0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":1513438000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":106787,"accession_number":"0001628280-26-011941","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2026-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BeOne Medicines FY2025 revenue $5.34B (+40% YoY); guides FY2026 $6.2-6.4B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $5.34B full year (+40% YoY); Q4 revenue $1.5B (+33% YoY).","GAAP net income $286.9M vs loss $644.8M prior year; diluted EPS $2.53 vs loss $6.12.","BRUKINSA global sales $3.9B (+49% YoY); Q4 sales $1.1B (+38%).","Non-GAAP diluted EPS $8.09; Adjusted income from operations $1.1B from $45M prior year.","FY2026 revenue guidance $6.2B-$6.4B; management cites pipeline strength and global leadership."],"consensus_eps_estimate":null,"consensus_eps_actual":0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":5343033000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123093,"accession_number":"0001651308-25-000153","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2025-12-19T23:59:59+00:00","items":["1.02"],"status":"ready","headline":"BeOne Medicines terminates CMB credit facility after refinancing with new facilities agreement","summary_kind":"llm","event_type":"debt","confidence":"medium","bullets":["On Dec 16, 2025, used proceeds from Nov 2025 Facilities Agreement to fully repay CMB Credit Facility dated Dec 9, 2024.","All lender commitments, guarantees and security interests under CMB Credit Facility terminated.","No termination penalties incurred from the CMB Credit Facility termination.","The new Facilities Agreement involved HSBC as global coordinator and a syndicate of lenders."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123092,"accession_number":"0001651308-25-000151","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2025-12-18T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"BeOne Medicines promotes Lai Wang to President, Global Head of R&D effective Jan 1, 2026","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Dr. Lai Wang appointed President, Global Head of R&D, overseeing R&D, business development, and alliance management.","Promotion effective January 1, 2026; annual salary $750,000 with target bonus of 75% of base salary.","One-time RSU equity award of $10M vesting in equal annual installments over four years.","Dr. Wang had served as Global Head of R&D since April 2021 and joined the company in 2011.","No family relationships or material interests in transactions with directors or officers."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123091,"accession_number":"0001651308-25-000148","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2025-11-19T23:59:59+00:00","items":["1.01","2.03"],"status":"ready","headline":"BeOne Medicines secures $1B senior secured financing facilities with HSBC-led syndicate","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Facilities include $140M B1 revolver, $560M B2 term loan (USD), and ~$300M A term loan (RMB), totaling $1B.","B loan facilities mature 24 months from first draw; A loan matures 36 months. Interest margins: 2.40% (B loans), 0.65% (A loan).","Proceeds used for general corporate purposes including refinancing existing offshore indebtedness and working capital.","Covenants include minimum cash interest coverage 5.00x, net leverage ≤2.50x, minimum equity $2.7B, minimum cash $500M outside PRC.","Security includes pledges on equity interests and mortgage on New Jersey manufacturing/R&D facility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123090,"accession_number":"0001628280-25-049821","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2025-11-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BeOne Medicines Q3 2025: total revenue up 41% to $1.4B, GAAP EPS $1.09","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $1.41B, +41% YoY; BRUKINSA revenue $1.0B, +51% YoY.","GAAP diluted EPS $1.09; non-GAAP diluted EPS $2.65, up from $0.48 a year ago.","GAAP net income $124.8M vs loss $121.4M in Q3 2024; adjusted net income $303.7M.","47 abstracts accepted at ASH 2025; pipeline advances with sonrotoclax (BCL2 inhibitor) and BTK CDAC BGB-16673.","Free cash flow $354.5M, up 548% from $54.7M in Q3 2024."],"consensus_eps_estimate":null,"consensus_eps_actual":0.15,"consensus_revenue_estimate":null,"consensus_revenue_actual":3844863000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139785,"accession_number":"0001651308-25-000136","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2025-08-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BeOne Medicines files STAR Interim Report; details R&D spend by key products for H1 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total R&D expenses $1,007M for H1 2025, up from $915M in H1 2024.","BCL2 inhibitor (BGB-11417) R&D spending surged to $94M from $39M YoY.","CDAC (BGB-16673) R&D increased to $27M from $6M; CDK4 (BGB-43395) to $10M from $2M.","Zanubrutinib R&D flat at $63M; Tislelizumab R&D up to $40M from $34M.","Filing includes PRC GAAP vs U.S. GAAP reconciliation for share-based comp, income taxes, leasing."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139784,"accession_number":"0001628280-25-041082","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2025-08-25T23:59:59+00:00","items":["1.01","2.03","7.01","9.01"],"status":"ready","headline":"BeOne sells IMDELLTRA ex-China royalty rights to Royalty Pharma for up to $950M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Upfront payment of $885M; option to sell additional royalties within 12 months for up to $65M.","BeOne retains share of royalty on annual ex-China net sales above $1.5B and all other Amgen collaboration rights.","IMDELLTRA is a DLL3-targeting bispecific T-cell engager approved in US for ES-SCLC after platinum chemo.","Transaction expected to close shortly; proceeds provide operational and strategic flexibility."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":139783,"accession_number":"0001651308-25-000131","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2025-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BeOne Medicines Q2 2025 revenues jump 42% to $1.3B; GAAP EPS $0.84","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenues $1.315B vs $929M YoY (+42%); BRUKINSA revenues up 49% to $950M.","GAAP net income $94.3M ($0.84 diluted EPS/ADS) vs loss of $120.4M a year ago.","Non-GAAP diluted EPS $2.25, adjusted income from operations $274.9M (up 467% YoY).","Free cash flow positive $219.8M vs negative $205.5M in Q2 2024.","Company expects 20+ R&D milestones in next 18 months across hematology and solid tumors."],"consensus_eps_estimate":null,"consensus_eps_actual":0.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":2432579000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157351,"accession_number":"0001104659-25-052750","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K12G3","filed_at":"2025-05-27T23:59:59+00:00","items":["1.01","3.03","8.01","5.02","5.03","9.01"],"status":"ready","headline":"BeiGene completes redomestication to Switzerland, renamed BeOne Medicines Ltd.","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Effective May 27, 2025, BeiGene continued from Cayman Islands to Switzerland, becoming BeOne Medicines Ltd.","New Swiss Articles and Organizational Regulations govern shareholder rights; ADSs continue on Nasdaq under ONC.","Executive employment agreements executed with CEO Oyler ($1.133M base), President Wu (RMB 6.0M), CFO Rosenberg ($660K), R&D head Wang (RMB 4.59M), and GC Lee ($654K).","Amended deposit agreement with Citibank and new indemnification agreements for directors and officers adopted.","Ordinary shares listed on HKEX (06160) and Shanghai STAR Market (688235) remain unchanged."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157357,"accession_number":"0001651308-25-000084","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2025-05-21T23:59:59+00:00","items":["5.07"],"status":"ready","headline":"BeiGene shareholders re-elect all director nominees and approve share issuance/repurchase mandates at AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Re-elected directors Hooper (956M for), Krishana (890M for), Wang (987M for), Yi (846M for), Sharp (985M for).","Approved 20% share issuance mandate (718M for, 277M against) and 10% share repurchase mandate (995M for, 99K against).","Approved Connected Person Placing Authorization for Amgen to maintain shareholding for up to 5 years, renewable annually.","Ratified Ernst & Young as independent auditors for FY2025 (989M for, 6M against).","Advisory say-on-pay passed with 875M for, 120M against."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.15,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157356,"accession_number":"0001651308-25-000078","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2025-05-13T23:59:59+00:00","items":["3.02"],"status":"ready","headline":"BeiGene issues 133M shares internally for re-domiciliation from Cayman to Switzerland","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Issued 133,000,000 ordinary shares to subsidiary BGNC2 in exchange for 13.7% of BeiGene UK Ltd.","Shares will be deemed treasury shares under Swiss law upon completion of planned re-domiciliation.","Issuance relies on Section 4(a)(2) exemption; shares will be cancelled if re-domiciliation abandoned.","Shares held for benefit of equity award holders under the 2016 Share Option and Incentive Plan.","Swiss issuance stamp tax and withholding tax exemptions apply as shares are created before re-domiciliation."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157355,"accession_number":"0001651308-25-000074","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BeiGene reports Q1 2025 revenue $1.1B (+49% YoY); first GAAP profitable quarter with net income $1.3M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $1.1B (+49% YoY); BRUKINSA sales $792M (+62%), now overall BTKi leader.","First GAAP profitable quarter: net income $1.3M vs loss $251M in Q1 2024; adjusted net income $136M.","Adjusted diluted EPS $1.22 vs ($1.40) prior year; operating cash flow significantly improved.","Shareholder approved renaming to BeOne Medicines and redomicile to Switzerland; investor R&D Day June 26."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":1117279000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157354,"accession_number":"0001651308-25-000066","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2025-04-29T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"USPTO invalidates all challenged claims of Pharmacyclics patent in BeiGene's BRUKINSA® PGR","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["USPTO Final Written Decision invalidates all claims of Pharmacyclics' U.S. Patent No. 11,672,803 challenged by BeiGene in post-grant review.","Patent is part of infringement lawsuit against BeiGene's BTK inhibitor BRUKINSA® (zanubrutinib) filed by Pharmacyclics in 2023.","BeiGene filed PGR petition on November 1, 2023; USPTO decision is appealable by Pharmacyclics."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157353,"accession_number":"0001651308-25-000063","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"BeiGene shareholders approve redomestication from Cayman Islands to Switzerland at EGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Special resolution to deregister in Cayman and continue to Switzerland passed with ~1.035B votes for, ~31K against.","Related amendment and restatement of articles (Proposed Swiss Articles) approved with similar overwhelming support.","Ernst & Young AG elected as Swiss statutory auditor until first AGM post-continuation; ~1.029B votes for.","Continuation remains subject to conditions and is expected to close later this year.","Quorum of ~74.6% of outstanding shares was present at the Extraordinary General Meeting on April 28, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.15,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157352,"accession_number":"0001651308-25-000057","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2025-04-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BeiGene files 2024 STAR annual report; US GAAP revenue $3.81B, gross margin down","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $3.81B in 2024, up 55% YoY from $2.46B; gross margin 85.1% vs 84.5% prior year.","China revenue $1.41B (gross margin 62.9%, down from 68.0%); ex-China revenue $2.40B (97.1% vs 98.0%).","Total R&D expenses $1.95B, up 10% YoY; zanubrutinib R&D $129M, tislelizumab $69M, Bcl-2 $100M.","Key product sales 5.0M vials in 2024; inventory 2.6M vials as of Dec 31, 2024.","Differences between PRC GAAP and US GAAP outlined for share-based comp and lease accounting."],"consensus_eps_estimate":null,"consensus_eps_actual":0.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":1117279000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175730,"accession_number":"0001651308-25-000029","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2025-02-27T23:59:59+00:00","items":["2.02","9.01","8.01"],"status":"ready","headline":"BeiGene Q4 revenue jumps 78% to $1.13B; BRUKINSA sales double; guides FY25 $4.9-5.3B","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue Q4 $1.13B (+78% YoY); full year $3.81B (+55% YoY).","BRUKINSA global revenue Q4 $828M (+100%); full year $2.6B (+105%).","Full year 2025 revenue guidance $4.9-$5.3B; anticipate positive GAAP operating income in 2025.","GAAP operating loss narrowed to $79M in Q4 from $384M; achieved positive non-GAAP operating income of $79M.","Advanced 6 NMEs in Q4 and 13 in full year; plan to change name to BeOne Medicines Ltd., ticker ONC."],"consensus_eps_estimate":1.1918,"consensus_eps_actual":-0.47,"consensus_revenue_estimate":null,"consensus_revenue_actual":3810241000.0,"consensus_period":"2024-FY","consensus_source":"xbrl+finnhub","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":175729,"accession_number":"0001651308-25-000012","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"BeiGene expects positive operating income for FY 2025 under US GAAP at J.P. Morgan conference","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Announced at 43rd Annual J.P. Morgan Healthcare Conference on Jan 13, 2025.","Expects to achieve positive operating income for full year 2025 per US GAAP.","Guidance does not assume any new material business development or unusual/non-recurring items.","Replay available on BeiGene's investor website for 30 days."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192669,"accession_number":"0001651308-24-000171","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2024-12-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BeiGene to change Nasdaq ticker symbol from BGNE to ONC effective Jan 2, 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["ADSs will trade under new ticker 'ONC' starting January 2, 2025.","Current ticker symbol 'BGNE' will be discontinued on that date.","No change to ADS terms or underlying ordinary shares.","Company expects seamless transition with no impact on trading."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192668,"accession_number":"0001651308-24-000164","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2024-12-10T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"BeiGene enters $400M unsecured credit facility with China Merchants Bank","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Facility dated Dec 9, 2024; $400M uncommitted, unsecured, revolving; SOFR-based floating rate.","Proceeds for daily operations and refinancing existing working capital loans.","Company plans to repay $300M of existing $380M drawn facility in Dec 2024; remaining $80M in Jan 2025.","Covenants include liabilities-to-equity ratio, minimum consolidated net assets and cash balance tested quarterly.","No borrowings outstanding under new facility as of filing date."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192667,"accession_number":"0001651308-24-000157","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2024-11-19T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BeiGene settles BRUKINSA patent litigation; generic entry no earlier than June 15, 2037","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Settlement with MSN allows generic BRUKINSA in U.S. no earlier than June 15, 2037, subject to customary accelerations.","Composition of matter patent expiring April 2034 was not challenged by MSN in the litigation.","Patent litigation against Sandoz also dismissed; all ANDA suits for BRUKINSA now resolved.","Parties filed joint stipulation to dismiss; settlement submitted to FTC and DOJ for review."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192666,"accession_number":"0001651308-24-000154","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2024-11-14T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BeiGene plans to change name to BeOne Medicines Ltd.; ticker to become ONC","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Name change to BeOne Medicines Ltd. subject to shareholder approval at a future meeting.","Nasdaq ticker symbol will change to 'ONC' upon completion of the name change.","Rebranding reflects commitment to develop innovative cancer medicines through global partnerships.","Shareholders urged to read definitive proxy statement when filed with the SEC."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192665,"accession_number":"0001651308-24-000150","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"BeiGene Q3 revenue $1.0B (+28% YoY); BRUKINSA global revenue $690M; positive non-GAAP OP income","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue $1,001.6M (+28% YoY); product revenue $993.4M (+67% YoY).","GAAP operating loss narrowed to $120.3M from $134.0M; adjusted operating income $65.6M vs loss $16.3M.","BRUKINSA global revenue $690M; now #1 in new patient starts for frontline and R/R CLL in U.S.","Four NMEs entered clinic in Q3 (eight YTD); on track for 10+ in 2024; sonrotoclax & BGB-16673 in late-stage.","CEO cites strong momentum in hematology and solid tumor pipeline expansions globally."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.36,"consensus_revenue_estimate":null,"consensus_revenue_actual":2682417000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":192664,"accession_number":"0001651308-24-000139","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2024-10-28T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BeiGene announces death of independent director Donald W. Glazer","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Mr. Glazer, independent director since 2013, chaired nominating and corporate governance committee.","Company expresses gratitude for his contributions and extends condolences to his family.","No replacement for the board vacancy has been announced at this time."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209117,"accession_number":"0001651308-24-000123","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2024-09-30T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BeiGene updates risk factors due to SEC comment letter on China operations","summary_kind":"llm","event_type":"regulatory","confidence":"low","bullets":["SEC staff requested restoration of certain risk factor language related to China operations from 2022 10-K.","Updated risk factors filed as Exhibit 99.1, restating those in 2023 10-K and subsequent 10-Qs.","Specific content of updated risk factors not detailed in available filing text."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209116,"accession_number":"0001651308-24-000118","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2024-09-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"BeiGene appoints Shalini Sharp to Board of Directors effective September 27, 2024","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Shalini Sharp, aged 49, appointed to fill vacancy on board expanded to 12 members.","Former CFO of Ultragenyx Pharmaceuticals (2012-2020) and board member of Neurocrine Biosciences and Organon.","Will receive equity awards valued at $400,000, annual cash compensation of $65,000 plus $17,500 for Audit Committee service.","Appointment effective September 27, 2024; she will serve as Class III director until 2025 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209115,"accession_number":"0001651308-24-000110","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2024-08-29T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BeiGene reports H1 2024 R&D expenses by product; total R&D up 10% YoY to $915M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Zanubrutinib R&D expense $62.9M in H1 2024, down 22% from $81.1M in H1 2023.","Tislelizumab R&D expense $34.5M in H1 2024, down 27% from $47.0M in H1 2023.","Bcl-2 (BGB-11417) R&D expense $38.6M in H1 2024, up 120% from $17.5M in H1 2023.","Total R&D expense $915.1M in H1 2024 vs $831.3M in H1 2023, +10.1% YoY.","R&D collaboration projects $82.5M in H1 2024, up from $23.3M in H1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":1680818000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209114,"accession_number":"0001651308-24-000097","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2024-08-07T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"BeiGene Q2 2024 revenue up 56% to $929M; achieves first non-GAAP operating income","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total revenue of $929 million, up 56% YoY; BRUKINSA global sales $637M (+107% YoY).","GAAP operating loss narrowed to $107M from $319M; non-GAAP operating income of $48M (positive inflection point).","Proposes redomicile from Cayman Islands to Switzerland; opens $800M biologics facility in New Jersey.","Pipeline: advancing sonrotoclax (BCL2i) and BGB-16673 (BTK degrader); over 15 solid tumor molecules in development.","BRUKINSA leads BTKi class in U.S. new patient starts across all approved indications."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.27,"consensus_revenue_estimate":null,"consensus_revenue_actual":1680818000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209113,"accession_number":"0001651308-24-000086","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2024-07-18T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"BeiGene names Aaron Rosenberg CFO effective July 22; Julia Wang resigns","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Aaron Rosenberg appointed CFO effective July 22; Julia Wang resigns effective July 19, stays as Senior Advisor through Aug 31.","Rosenberg receives $620k base salary, 60% target bonus, $5M equity award (mix of RSUs, options, PSUs).","Wang receives $930k severance (18 months base) plus $559.5k for bonus/benefits; 18-month accelerated vesting of prior equity grants.","Wang's resignation is not the result of any dispute or disagreement with BeiGene's board or management."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226982,"accession_number":"0001651308-24-000055","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["5.02","5.07","9.01"],"status":"ready","headline":"BeiGene shareholders approve equity plan share increases and director re-elections at AGM","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Approved Third Amended 2016 Share Option Plan, adding 92.82M shares to the reserve.","Approved Fourth Amended 2018 ESPP, increasing share availability by 5.07M shares.","Re-elected Class II directors Brandicourt, Glazer, Goller, Sanders with strong support.","Approved general mandates to issue up to 20% and repurchase up to 10% of shares.","Approved RSUs and PSUs to CEO John Oyler ($6M each) and other executive grants."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226981,"accession_number":"0001651308-24-000049","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"BeiGene Q1 2024 revenue up 82% to $752M; BRUKINSA sales $489M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Total Q1 product revenue $747M (+82% YoY); total revenue $752M; BRUKINSA revenue $489M.","BRUKINSA U.S. sales grew 153% and Europe 243% YoY; fifth FDA approval gives broadest BTKi label.","GAAP operating loss narrowed to $261M from $371M; adjusted operating loss $147M vs $276M.","TEVIMBRA now approved in U.S. and Europe; advancing late-stage pipeline including sonrotoclax and BTK CDAC.","Company says progressing toward sustainable profitability with improved operating leverage."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.19,"consensus_revenue_estimate":null,"consensus_revenue_actual":751652000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226980,"accession_number":"0001651308-24-000043","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2024-04-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"BeiGene provides additional 2023 financial data including regional gross margins and product R&D","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Total revenue $2.46B; China gross margin 68.0% (2022: 67.1%), ex-China 98.0% (98.3%).","R&D expense by product: zanubrutinib $158M, tislelizumab $84M, pamiparib $9M, ociperlimab $78M.","Total R&D expenses $1.78B in 2023 vs $1.64B in 2022; internal R&D $1.13B.","Key products produced 5.0M vials, sold 3.88M vials; inventory 2.67M vials as of Dec 31, 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":226979,"accession_number":"0001651308-24-000039","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2024-04-23T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"EC approves BeiGene's tislelizumab for three NSCLC indications in EU","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["EC approved tislelizumab on April 23, 2024 for first-line squamous NSCLC, first-line non-squamous PD-L1≥50%, and second-line after prior platinum therapy.","Approval based on three Phase 3 RATIONALE trials (307, 304, 303) enrolling 1,499 patients, showing PFS and OS benefits.","This is tislelizumab's second EU approval; previously approved for ESCC; brand will unify under TEVIMBRA later in 2024.","BeiGene plans to launch in first EU countries in 2024; over 900,000 patients prescribed tislelizumab globally."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245918,"accession_number":"0001651308-24-000032","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2024-03-20T23:59:59+00:00","items":["5.02","8.01","9.01"],"status":"ready","headline":"BeiGene appoints Titus Ball as principal accounting officer; amends director compensation","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Titus Ball named principal accounting officer effective March 19, 2024; succeeded Julia Wang, who remains CFO.","Ball joined in Aug 2023 as VP, Chief Accounting Officer; prior roles at Carlisle, KPMG, PwC.","Independent director cash retainers increased: Nominating Committee chair to $20,000 (+$2K), members to $10,000 (+$1K).","No changes to equity award structure ($400K initial and annual grant, 50/50 options/RSUs).","Amended policy effective April 1, 2024; full text filed as Exhibit 10.1."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245917,"accession_number":"0001651308-24-000028","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2024-03-15T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA approves BeiGene's TEVIMBRA for ESCC after prior chemo; available H2 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approved TEVIMBRA (tislelizumab) for ESCC after prior chemo; first US indication; available H2 2024.","Approval based on RATIONALE 302: median OS 8.6 vs 6.3 months (HR=0.70, p=0.0001).","FDA also reviewing BLAs for first-line ESCC (target July 2024) and G/GEJ adenocarcinoma (target Dec 2024).","Over 900,000 patients prescribed TEVIMBRA globally; 17+ registration-enabling trials ongoing.","Safety profile favorable over chemo; common adverse reactions include increased glucose, decreased hemoglobin, fatigue."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245916,"accession_number":"0001651308-24-000021","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2024-03-08T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"BeiGene files patent suits against Sandoz and MSN to block generic BRUKINSA until 2034","summary_kind":"llm","event_type":"litigation","confidence":"high","bullets":["Filed Hatch-Waxman infringement suits in District of New Jersey after Sandoz and MSN filed ANDAs with Paragraph IV certifications.","Composition of matter patent for BRUKINSA not challenged; remains intact and expires in 2034.","Complaints seek permanent injunction to prevent generic commercialization before expiration of asserted Orange Book patents.","ANDA litigation common in pharma; additional notices from other generic companies may follow."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":245915,"accession_number":"0001651308-24-000011","cik":1651308,"company_name":"BeOne Medicines Ltd.","ticker":"ONC","form_type":"8-K","filed_at":"2024-02-26T23:59:59+00:00","items":["2.02","8.01","9.01"],"status":"ready","headline":"BeiGene Q4 revenue $634M (+67% YoY); BRUKINSA sales $413M (+135%); operating loss narrows","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Record total revenue $634M in Q4 (+67% YoY) and $2.5B full year (+74%); product revenue $630.5M (+86%).","BRUKINSA global sales $413M in Q4 (+135% YoY) and $1.3B full year (+129%); U.S. revenue $313M in Q4.","GAAP operating loss $383.8M in Q4, down 18% YoY; adjusted operating loss $267.2M, down 28%.","FDA approved BRUKINSA label update for PFS superiority in CLL; EU approved for R/R follicular lymphoma.","Advanced pipeline: sonrotoclax Phase 3 in CLL started; BTK CDAC BGB-16673 early data; TEVIMBRA CHMP positive opinion for NSCLC."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.65,"consensus_revenue_estimate":null,"consensus_revenue_actual":2458779000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":239441148528.7316,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":null}